BRUKINSA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Cyprus, Ecuador, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug BRUKINSA contains one active pharmaceutical ingredient (API):

1	Zanubrutinib UNII AG9MHG098Z - ZANUBRUTINIB
	Zanubrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signalling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion.
	Read more about Zanubrutinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BRUKINSA Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EL03		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EL Bruton's tyrosine kinase (BTK) inhibitors
Discover more medicines within L01EL03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	6861-MEE-1221
EE	Ravimiamet	1867798
ES	Centro de información online de medicamentos de la AEMPS	1211576001
FR	Base de données publique des médicaments	65919841
IL	מִשְׂרַד הַבְּרִיאוּת	8764
IT	Agenzia del Farmaco	049782016
LT	Valstybinė vaistų kontrolės tarnyba	1093771
PL	Rejestru Produktów Leczniczych	100461024
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69200001
US	FDA, National Drug Code	72579-011